---
document_datetime: 2025-01-06 10:54:26
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zirabev-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: zirabev-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.8726597
conversion_datetime: 2025-12-22 16:21:16.841254
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Zirabev

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0032              | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product | 05/12/2024                          |                                             | Annex II                         |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0031           | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                | 08/11/2023   | 21/10/2024   | Annex II and PL   |                                                                                                                                                                                                                                                                       |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0029            | Renewal of the marketing authorisation.                                                                                                                                                                                                                      | 14/09/2023   | 06/11/2023   | SmPC and PL       | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Zirabev in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IB/0030           | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                 | 24/10/2023   | n/a          |                   |                                                                                                                                                                                                                                                                       |
| PSUSA/403/2 02202 | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                                                    | 13/10/2022   | 09/12/2022   | SmPC and PL       | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/403/202202.                                                                                                                              |
| IB/0028           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 26/07/2022   | 09/12/2022   | SmPC and PL       |                                                                                                                                                                                                                                                                       |
| IA/0026           | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                | 28/03/2022   | 01/07/2022   | SmPC              |                                                                                                                                                                                                                                                                       |
| IB/0025           | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                         | 04/01/2022   | n/a          |                   |                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| N/0024            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                             | 01/10/2021   | 01/07/2022   | PL          |                                   |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|-----------------------------------|
| PSUSA/403/2 02102 | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                                                    | 30/09/2021   | n/a          |             | PRAC Recommendation - maintenance |
| IB/0023           | B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                                                                                                       | 13/09/2021   | n/a          |             |                                   |
| II/0019           | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                          | 17/06/2021   | n/a          |             |                                   |
| IB/0021           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 04/05/2021   | 01/07/2022   | SmPC and PL |                                   |
| IB/0020           | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                       | 04/05/2021   | n/a          |             |                                   |
| IB/0018           | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                | 22/03/2021   | n/a          |             |                                   |
| IB/0017           | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other                                                                                                                                                                | 08/03/2021   | n/a          |             |                                   |

<div style=\"page-break-after: always\"></div>

|                   | changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                               |            |            |             |                                   |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| IB/0016           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 07/12/2020 | 22/12/2020 | SmPC and PL |                                   |
| IB/0015           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                               | 30/10/2020 | 22/12/2020 | SmPC and PL |                                   |
| IB/0014           | B.I.d.z - Stability of AS - Other variation                                                                                                                                                                                                                  | 28/10/2020 | n/a        |             |                                   |
| PSUSA/403/2 02002 | Periodic Safety Update EU Single assessment - bevacizumab                                                                                                                                                                                                    | 01/10/2020 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0013           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 25/09/2020 | 27/10/2020 | SmPC and PL |                                   |
| IB/0012           | B.II.b.4.f - Change in the batch size (including batch size ranges) of the finished product - The scale for a biological/immunological medicinal product is increased/decreased without process change (e.g. duplication of line)                            | 31/07/2020 | n/a        |             |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0009   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                     | 01/04/2020   | n/a        |                 |             |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-------------|
| IB/0010   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                                                                                                                                                                                                                                     | 24/03/2020   | n/a        |                 |             |
| IA/0008   | B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                          | 06/03/2020   | n/a        |                 |             |
|           | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 13/02/2020   | 27/10/2020 | Annex II and PL | IAIN/0007/G |
| IB/0006   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time                                                                                                                                                                                                                                                                                                                                                                | 03/02/2020   | n/a        |                 |             |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             | data   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------|
| IB/0005   | B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 17/01/2020 | 27/10/2020 | SmPC and PL |        |
| IB/0004/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 19/12/2019 | 16/01/2020 | SmPC and PL |        |

<div style=\"page-break-after: always\"></div>

| IAIN/0003         | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation   | 31/10/2019   | 16/01/2020   | SmPC, Annex II, Labelling and PL   |                                   |
|-------------------|--------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-----------------------------------|
| PSUSA/403/2 01902 | Periodic Safety Update EU Single assessment - bevacizumab                                        | 05/09/2019   | n/a          |                                    | PRAC Recommendation - maintenance |
| N/0001            | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 09/04/2019   | 16/01/2020   | PL                                 |                                   |